Search

Viking Therapeutics Inc

Затворен

СекторЗдравеопазване

24.79 2.31

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24

Максимум

24.86

Ключови измерители

By Trading Economics

Приходи

30M

-128M

EPS

-1.1

Служители

65

EBITDA

30M

-128M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+275.84% upside

Дивиденти

By Acuity

Следващи печалби

28.10.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-863M

3.2B

Предишно отваряне

22.48

Предишно затваряне

24.79

Viking Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.10.2026 г., 20:02 ч. UTC

Social Media

Shares of Viking Therapeutics Inc fell sharply as the company prepares to report earnings on October 28th, breaking a recent trend of higher daily closes.

22.10.2026 г., 20:07 ч. UTC

News
Correlated Moves
Macro Event

Viking Therapeutics sees increased bearish sentiment with 6.55k puts traded, 1.6 times expected volume, ahead of its Q3 results on October 28, 2026.

21.10.2026 г., 23:06 ч. UTC

News

Viking Therapeutics Inc will report its third-quarter financial results on October 28, 2026, and host a conference call at 4:30 p.m. ET.

20.10.2026 г., 23:06 ч. UTC

News

Viking Therapeutics Inc is trading higher in after-market hours.

19.10.2026 г., 23:41 ч. UTC

Viking Therapeutics Inc shares are modestly higher in after-market trading, reaching their highest point since Monday's close after bouncing back from earlier lows.

16.10.2026 г., 20:02 ч. UTC

Social Media
Correlated Moves

Shares of Viking Therapeutics Inc are declining amid a broader downturn in the biotechnology sector, with the SPDR S&P Biotech ETF also lower.

15.10.2026 г., 20:04 ч. UTC

News
Social Media

Viking Therapeutics shares advanced after Oppenheimer maintained an "outperform" rating with a $120 price target and UBS initiated coverage with a $94 price target.

14.10.2026 г., 23:02 ч. UTC

News
Social Media

Viking Therapeutics shares advanced in after-market trading after UBS initiated coverage with a Buy rating and a price target of $94.00.

13.10.2026 г., 19:51 ч. UTC

Viking Therapeutics Inc shares fell sharply, reaching their lowest point of the day and remaining well below their 20-day moving average.

9.10.2026 г., 20:07 ч. UTC

Correlated Moves
News
Social Media

Viking Therapeutics is seeing increased interest amid reports of a potential bidding war, with speculation about suitors including LLY and positive momentum in the biotech sector.

8.10.2026 г., 20:07 ч. UTC

Social Media

Shares of Viking Therapeutics Inc declined notably during the session, continuing a downward trend since Wednesday's close, reaching a low before a slight recovery.

7.10.2026 г., 20:08 ч. UTC

News
Event
Social Media

Viking Therapeutics Inc shares are trading higher as Truist Securities lowers its price target to $85.00 while maintaining a Buy rating.

6.10.2026 г., 23:01 ч. UTC

Event

Viking Therapeutics Inc has initiated an exploratory oral maintenance dosing study of VK2735, with the stock advancing in after-market trading following the announcement.

5.10.2026 г., 20:06 ч. UTC

Social Media
News

Viking Therapeutics Inc shares fell sharply, reflecting a significant decline from a recent high of $43.10, closing down notably since Friday.

2.10.2026 г., 20:07 ч. UTC

Viking Therapeutics Inc shares fell sharply, continuing a decline since Thursday's close and closing significantly below the 20-day moving average.

1.10.2026 г., 23:01 ч. UTC

Social Media

Viking Therapeutics Inc. is seeing increased social media attention, with its stock rising in after-market trading to $30.51 amid acquisition speculation.

30.09.2026 г., 20:07 ч. UTC

Social Media

Viking Therapeutics shares are advancing today as discussions on VK2735's weight loss data gain traction, with Cantor setting a $100 price target.

29.09.2026 г., 23:05 ч. UTC

Viking Therapeutics Inc is seeing a modest increase in after-market trading, recovering from an initial low before settling back slightly.

28.09.2026 г., 20:03 ч. UTC

News
Social Media

Viking Therapeutics Inc shares fell sharply amid online posts about its VK2735 drug, raising concerns of panic selling despite promising trial results.

25.09.2026 г., 20:02 ч. UTC

Social Media

Viking Therapeutics shares are lower amid volatility, despite positive trial data, as concerns over a recent capital raise and share sales at $35 persist.

24.09.2026 г., 20:03 ч. UTC

News
Social Media

Viking Therapeutics Inc. shares fell sharply after announcing a $500 million capital raise, including 7.86 million shares priced at $35.00 each, amid dilution concerns.

23.09.2026 г., 23:01 ч. UTC

News
Social Media

Viking Therapeutics plans to raise $400 million through stock and convertible notes offerings, causing significant after-hours trading decline amid dilution concerns.

22.09.2026 г., 23:01 ч. UTC

News
Social Media

Viking Therapeutics Inc gained after Oppenheimer raised its price target for VK2735 from $100 to $120, citing strong trial results and increased retail sentiment.

21.09.2026 г., 23:01 ч. UTC

Social Media

Viking Therapeutics Inc is advancing in after-market trading following notable social media interest, breaking a streak of ten consecutive lower daily closes.

18.09.2026 г., 20:07 ч. UTC

Viking Therapeutics Inc is declining, continuing a downward trend as the broader market marks its tenth consecutive session of losses.

17.09.2026 г., 19:16 ч. UTC

Social Media

Viking Therapeutics Inc is trading higher as social media buzz surrounds VK2735 ahead of its anticipated Phase 3 trials, despite recent declines.

16.09.2026 г., 23:06 ч. UTC

Viking Therapeutics Inc is trading modestly higher in after-market hours, following eight consecutive lower daily closes and recent broader market declines.

15.09.2026 г., 23:02 ч. UTC

Viking Therapeutics Inc shares are higher during after-market hours, reflecting broader market trends despite recent economic indicators suggesting a slowdown in manufacturing.

14.09.2026 г., 19:36 ч. UTC

Viking Therapeutics Inc shares are lower, continuing a trend of declines amid broader market weakness and rising crude oil prices affecting sentiment.

11.09.2026 г., 23:06 ч. UTC

Viking Therapeutics Inc. shares are higher in after-market trading, despite routine fluctuations, and remain below their 20-day moving average.

Сравнение с други в отрасъла

Ценова промяна

Viking Therapeutics Inc Прогноза

Ценова цел

By TipRanks

275.84% нагоре

12-месечна прогноза

Среден 91.706 USD  275.84%

Висок 125 USD

Нисък 38 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за Viking Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

18 ratings

17

Купи

1

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
help-icon Live chat